| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS. CEO | MSE Exchange | INE987B01026 ISIN |
| IN Country | 3,946 Employees | 20 Nov 2025 Last Dividend | 26 Nov 2015 Last Split | - IPO Date |
NATCO Pharma Limited is an established pharmaceutical entity engaged in the development, production, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs). With a focus on serving several therapeutic areas, particularly oncology, the company has made significant contributions to the pharmaceutical industry by offering innovative and effective healthcare solutions. Founded in 1981 and headquartered in Hyderabad, India, NATCO Pharma has expanded its reach to approximately 50 countries worldwide, demonstrating its capability to address global health challenges. Besides its primary focus on pharmaceuticals, the company also extends its expertise to the agriculture sector by offering agrochemicals and biological pest management solutions, marking its diversity and commitment towards improving health and food security.
NATCO Pharma provides a wide range of finished dosage formulations catering to various therapeutic areas including but not limited to cancers (blood, liver, kidney, lung, brain, breast, ovary, etc.). These formulations embody the company's commitment to combating critical illnesses through innovative pharmaceutical solutions.
The company specializes in the production of APIs with a strong focus on oncology. Additionally, it develops APIs for central nervous system disorders, pain management, and cardiovascular care, demonstrating its comprehensive approach towards addressing diverse medical conditions.
NATCO Pharma offers orthopedic solutions, notably bisphosphonates, which are available in both oral and injectable forms. These medications play a crucial role in the treatment and management of bone disorders.
The company's range of novel gastroenterology products offers treatments for chronic hepatitis-B and hepatitis-C, reflecting its commitment to tackling hard-to-cure liver diseases.
NATCO Pharma leverages its manufacturing expertise to provide contract manufacturing services, offering partners quality and efficiency in drug production.
Addressing the needs of patients with heart conditions and diabetes, NATCO provides effective treatments for hypertension, stable angina, and congestive heart failure (CHF), highlighting its interdisciplinary approach to healthcare.
Extending its innovative approach beyond human health, NATCO offers agrochemicals and biological pest management solutions aiming at the improvement of crop protection and food security.